TW201726712A - 藉由使用ｃｄ－ｒａｐ前驅蛋白改善ｃｄ－ｒａｐ製程中之表現與摺疊 - Google Patents

藉由使用ｃｄ－ｒａｐ前驅蛋白改善ｃｄ－ｒａｐ製程中之表現與摺疊 Download PDF

Info

Publication number
TW201726712A
TW201726712A TW105130213A TW105130213A TW201726712A TW 201726712 A TW201726712 A TW 201726712A TW 105130213 A TW105130213 A TW 105130213A TW 105130213 A TW105130213 A TW 105130213A TW 201726712 A TW201726712 A TW 201726712A
Authority
TW
Taiwan
Prior art keywords
rap
composition
protein
sequence
buffer
Prior art date
Application number
TW105130213A
Other languages
English (en)
Chinese (zh)
Inventor
伊莎貝兒 舒歐爾托
朱迪瑟 史托曼斯
保羅 哈柏曼
伯納德 喬納柴
湯瑪士 史迪爾吉
艾克阿特 巴特尼基
沃爾克 傑斯柯
約金 沙斯
Original Assignee
賽諾菲公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 賽諾菲公司 filed Critical 賽諾菲公司
Publication of TW201726712A publication Critical patent/TW201726712A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
TW105130213A 2015-09-18 2016-09-19 藉由使用ｃｄ－ｒａｐ前驅蛋白改善ｃｄ－ｒａｐ製程中之表現與摺疊 TW201726712A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306458 2015-09-18
EP15306457 2015-09-18
EP15306950 2015-12-07

Publications (1)

Publication Number Publication Date
TW201726712A true TW201726712A (zh) 2017-08-01

Family

ID=57223637

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105130213A TW201726712A (zh) 2015-09-18 2016-09-19 藉由使用ｃｄ－ｒａｐ前驅蛋白改善ｃｄ－ｒａｐ製程中之表現與摺疊

Country Status (8)

Country Link
US (2) US10660852B2 (https=)
EP (1) EP3350204A2 (https=)
JP (1) JP6976254B2 (https=)
CN (1) CN108602866A (https=)
AU (2) AU2016321884B2 (https=)
CA (1) CA2998665A1 (https=)
TW (1) TW201726712A (https=)
WO (1) WO2017046314A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3766356B1 (en) * 2018-03-16 2025-01-15 Eco-Geo Bio-Technology Company Limited Method to enhance the proteolysis efficiency of pepsin or trypsin
CN108410803B (zh) * 2018-03-28 2019-02-05 湖南源品细胞生物科技有限公司 一种诱导脂肪干细胞成软骨分化的培养方法和培养液
FR3092339B1 (fr) * 2019-02-05 2024-04-12 Michelin & Cie Cellule, notamment levure, resistante au phloroglucinol
CN113024675A (zh) * 2020-12-29 2021-06-25 山东第一医科大学(山东省医学科学院) 一种hb-nc4重组蛋白及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95495A (en) * 1989-08-29 1996-10-16 Hoechst Ag Fusion proteins their preparation and use
AU5705600A (en) * 1999-06-30 2001-01-22 Takeda Chemical Industries Ltd. Novel polypeptide and dna thereof
JP4579378B2 (ja) * 1999-06-30 2010-11-10 武田薬品工業株式会社 新規ポリペプチドおよびそのｄｎａ
EP1604693A1 (en) * 2004-06-09 2005-12-14 Scil Technology GmbH In situ forming scaffold, its manufacturing and use
CN102940878A (zh) 2006-10-06 2013-02-27 Scil技术股份有限公司 脊柱髓核植入物
EP2547700A1 (en) * 2010-03-17 2013-01-23 Universität Regensburg Peptides or antibodies which bind to melanoma inhibitory activity (mia) protein
BR112012027361A2 (pt) * 2010-04-27 2021-04-27 Scil Technology Gmbh formulação mia/cd-rap estável.

Also Published As

Publication number Publication date
EP3350204A2 (en) 2018-07-25
CA2998665A1 (en) 2017-03-23
US10660852B2 (en) 2020-05-26
AU2016321884A1 (en) 2018-04-12
AU2021202110A1 (en) 2021-05-06
WO2017046314A2 (en) 2017-03-23
CN108602866A (zh) 2018-09-28
US20190046442A1 (en) 2019-02-14
JP6976254B2 (ja) 2021-12-08
JP2018527030A (ja) 2018-09-20
WO2017046314A3 (en) 2017-05-26
US20200268663A1 (en) 2020-08-27
AU2016321884B2 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
AU2021202110A1 (en) Improvement of expression and folding in the manufacturing process of CD-RAP by using a CD-RAP precursor protein
Liu et al. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX
Zheng et al. Enzyme-instructed and mitochondria-targeting peptide self-assembly to efficiently induce immunogenic cell death
Kitakaze et al. Protease-resistant modified human β-hexosaminidase B ameliorates symptoms in GM2 gangliosidosis model
JP5989641B2 (ja) リポタンパク質製剤及びその製造方法
Sung et al. Swedish nerve growth factor mutation (NGFR100W) defines a role for TrkA and p75NTR in nociception
CN105142657A (zh) 软骨结合型融合蛋白
EP3725326B1 (en) Plasminogen for treating osteoarthritis
He et al. Rectifying the crosstalk between the skeletal and immune systems Improves osteoporosis treatment by core–shell nanocapsules
Arnold et al. Calcium negatively regulates meprin β activity and attenuates substrate cleavage
Spencer et al. Calpain translocation during muscle fiber necrosis and regeneration in dystrophin-deficient mice
US20190388346A1 (en) Methods and compositions for treating osteoarthritis and promoting cartilage formation
JP2009528339A (ja) ペプチド及びその使用
Jonsson et al. Extracts from tumors causing oncogenic osteomalacia inhibit phosphate uptake in opossum kidney cells
WO2014194428A1 (en) Targeted heparan sulfatase compounds
WO2011024942A1 (ja) マトリックスメタロプロテアーゼ－２（ｍｍｐ－２）阻害剤
Lewandowska-Goch et al. Design and Structure–Activity Relationship of a Potent Furin Inhibitor Derived from Influenza Hemagglutinin
TWI586802B (zh) 重組成對鹼性胺基酸蛋白酶之調配物
EP2087905A2 (en) Interleukin-20 for treating and diagnosing conditions associated with neovascularisation
Ishaq et al. Lysosomal cysteine proteases are mediators of cell death in macrophages following exposure to amorphous silica nanoparticles
Fu et al. Virus-inspired lipopeptide-derived nucleic acid delivery to cartilage for osteoarthritis therapy
US9670250B2 (en) Alpha-helical peptidomimetic inhibitors and methods using same
Naing Solution Structure and Biochemistry of an Intramembrane Aspartyl Protease (LAP)
RU2777504C2 (ru) Способы и композиции для лечения повреждения хряща и артрита
Dobi Lipid-based approaches to optimize the effectiveness of innovative drug modulators in Cystic Fibrosis